The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
175 jobs Number of planned job losses
Announcement Date
15 June 2021
Employment effect (start)
15 June 2021
Foreseen end date
Description
As announced on 15 June 2021, the UK-based pharmaceutical company AstraZeneca will be closing its site in Wedel which will result in the dismissal of 175 employees in the production. The decision has been made as a reaction to the market demand for the products. A social plan will be implemented by the end of 2021.
In addition to the production site's closure, the headquarters will be relocated from Wedel to Hamburg. The new headquarters will allow AstraZeneca to continue to grow and implement new modern forms of working.
AstraZeneca has approximately 900 employees in Germany.
Eurofound (2021), AstraZeneca, Closure in Germany, factsheet number 104969, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/104969.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
